Abstract: 1-Phenyl-lower alkylimidazole-4- and/or 5-carboxamides of the formula ##STR1## in which Ph represents phenyl substituted by lower alkyl and/or by halogen, alk represents lower alkylidene, one of the radicals R.sub.1 and R.sub.2 is carbamoyl optionally substituted by lower alkyl or by lower alkanoyl and the other is hydrogen, lower alkyl, or carbamoyl optionally substituted by lower alkyl or by lower alkanoyl, and R.sub.3 represents hydrogen or lower alkyl, have anticonvulsive properties and can be used as anticonvulsives. They are manufactured as follows: in a compound of the formula ##STR2## in which R.sub.1 ' represents a radical R.sub.1 or X and R.sub.2 ' represents a radical X, or R.sub.1 ' represents a radical X and R.sub.2 ' represents a radical R.sub.

Abstract: N,N-(dibenzohexatrienylene)urea medicaments can be manufactured in a smooth one-step reaction by reacting a corresponding N,N-(dibenzohexatrienylene)amine with cyanic acid.

Abstract: 1-Phenyl-3-azabicyclo[3.1.0]hexane-2,4-diones of the formula ##STR1## wherein R.sub.1 is hydrogen, R.sub.2 is hydrogen, sulfo or acyl and R.sub.3 is hydrogen, or R.sub.1 is a saturated or unsaturated aliphatic, cycloaliphatic or cycloaliphatic-aliphatic carbon radical of up to and including 18, preferably of up to and including 12, carbon atoms, R.sub.2 is hydrogen, lower alkyl, sulfo or acyl and R.sub.3 is hydrogen or lower alkyl, and to salts thereof, and salts thereof, have valuable pharmacological properties and are effective aromatase inhibitors. They can therefore be used for the treatment of hormonal diseases, in particular mammary carcinomas.

Abstract: The instant invention relates to fluorinated cationic compounds of the formula ##STR1## wherein R.sub.f is a perfluoroalkyl or perfluoroalkoxy-perfluoroalkyl group;R.sub.1 is alkylene optionally interrupted by --O--, --S--, --SO.sub.2 --, --SO.sub.2 NR'--, --CO.sub.2 --, --NR'--, or --CONR'-- where R' is hydrogen or lower alkyl;m is 0, 1 or 2;R.sub.2 is linear or branched alkylene;R.sub.3, R.sub.4, and R.sub.5 independently of one another represent alkyl or arylalkyl groups which are unsubstituted or substituted by hydroxyl, lower alkoxy, halogen, cyano or by polyalkyleneoxy, or R.sub.3 and R.sub.4 together with the nitrogen atom to which they are attached represent a 5- or 6-membered heterocyclic radical or R.sub.3, R.sub.4 and R.sub.5 together with nitrogen atom that links them represent a substituted or unsubstituted pyridine ring; andA.sup..crclbar. represents the anion of an organic or inorganic acid; and their particular use as surfactants.

Abstract: A gel formation for oral administration having improved palatability comprising an effective hypocholesterolaemic amount of a uniform gelled dispersion of(a) between about 8 and about 20 percent by weight of a particulate, pharmaceutically acceptable, sparingly crosslinked non-digestible quaternary ammonium substituted polysytrene anion exchange resin having an average particle size below about 100 microns;(b) between about 4 and about 16 percent by weight of a pharmaceutically acceptable gelatin;(c) between about 0.015 and about 10 percent by weight of a natural or synthetic pharmaceutically acceptable sweetener;(d) between about 0.05 and about 2 percent by weight of a pharmaceutically acceptable organic acidulent;(e) between about 0.05 and about 5 percent by weight of one or more pharmaceutically acceptable flavoring or coloring agents or mixtures thereof; and(f) the remainder water.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is optionally substituted phenyl, pyridyl, thienyl, furyl, pyrrolyl, thiazolyl, or ribofuranosyl; X is oxygen, NR, or sulfur; R is hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and ring A is (a) an optionally substituted 5-8 membered monocycloalken-1,2-diyl; (b) an optionally substituted carbobicyclic ring of the formula ##STR2## wherein n and m are each independently one or two; or (c) an optionally substituted 5-6 membered heterocycle having one or two heteroatoms, the atoms of which are selected from carbon, oxygen, nitrogen, and sulfur. Also disclosed are tautomers of the above and pharmaceutically acceptable salts; compositions thereof; and methods of using the compounds, tautomer, or salts.

Abstract: Compounds of the formula ##STR1## in which R.sub.1 represents lower alkyl substituted by hydroxy or by protected hydroxy, R.sub.2 represents carboxy or functionally modified carboxy, and R.sub.3 represents optionally substituted 3-pyridyl or optionally substituted 4-pyridyl, and pharmaceutically acceptable salts of such compounds, have antibacterial activity. The compounds of the formula I can be manufactured according to processes known per se.

Abstract: The invention relates to a method for the detection of fungi and algae in animal or human tissues and body fluids, to preparations containing an optical whitening agent suitable for the method, and to a test pack for performing the method. The tissue sections or body fluid samples to be examined are treated with an optical whitening agent and observed using a fluorescence microscope. The invention permits a rapid and reliable diagnosis of fungal infections.

Abstract: 4-Acylresorcinol esthers of the formula ##STR1## in which R.sub.1 is lower alkyl, R.sub.2 is fluorinated lower alkyl, R.sub.3 is hydrogen, lower alkoxy, trifluoromethyl or halogen, alk is an alkylene or hydroxyalkylene radical which is uninterrupted or interrupted by oxygen, one of the radicals R.sub.4, R.sub.5 and R.sub.7 is a group of the formula --NH--C(.dbd.O)--R.sub.8, a radical R.sub.4 or R.sub.5 which differs from this is a radical R.sub.9 and a radical R.sub.7 which differs from this is a radical R.sub.10, R.sub.6 is hydrogen, lower alkyl, trifluoromethyl, halogen, carboxyl which is free, esterified or amidated, cyano or lower alkanoyl, R.sub.8 is carboxyl which is free, esterified or amidated or 5-tetrazolyl, R.sub.9 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl and R.sub.10 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, cyano or carboxyl which is free, esterified or amidated, and their salts have antiallergic and antiinflammatory properties.

Abstract: The invention relates to the use of ketenethioacetals of the formula ##STR1## in which R.sub.1 represents aryl or heteroaryl, R.sub.2 represents hydrogen, an optionally substituted hydrocarbon radical, heteroaryl, an acyl radical, a group of the formula --S(O).sub.m --R.sub.a, wherein m is 0, 1, or 2 and R.sub.a is an optionally substituted hydrocarbon radical; or optionally functionally modified sulpho, A represents an optionally substituted bivalent aliphatic hydrocarbon radical and n is 0 or 1, and pharmaceutically acceptable salts of such compounds that contain a salt-forming group, for the treatment of liver diseases, respiratory tract diseases and vascular diseases pharmaceutical preparations containing compounds of the formula I and novel compounds of the formula I. The compounds have liver-protecting and immunomodulating properties.

Abstract: The invention relates to novel 1,4-dihydropyridine-3-carboxylic acid phenoxyaliphatylphenyleneoxyalkyl esters of the formula ##STR1## in which Ac represents an acyl group, X represents oxy or optionally substituted imino, A represents a divalent aliphatic hydrocarbon radical interrupted by a group --X.sub.1 --Ph--X.sub.2 -- in which at least one of the radicals X.sub.1 and X.sub.2 represents oxy and a radical X.sub.1 or X.sub.2 that is other than oxy represents a direct bond, and Ph represents an optionally substituted phenylene radical, and R represents an optionally substituted phenyl, pyridyl or 1-oxidopyridyl, (1,3-dioxa)indanyl or benzofurazanyl radical, R.sub.1 represents an optionally substituted phenyl or indolyl radical, R.sub.2 represents an aliphatic hydrocarbon radical and R.sub.3 represents an aliphatic radical, cyano or amino, and acid addition salts thereof.

Abstract: Stabilized hydrogen peroxide disinfecting solutions containing diphosphonic acids (such as hydroxyethylidene diphosphonic acid), and glycerin are disclosed along with a disinfection method.

Abstract: Compounds of the formula ##STR1## in which R represents a carbocyclic or heterocyclic aryl radical, R.sub.1 represents lower alkyl, one of the groups R.sub.2 and R.sub.3 represents lower alkyl and the other represents lower alkyl, cyano aor amino, X represents oxygen or the group --NH--, Alk.sub.1 represents lower alkylene or optionally substituted phenyl-lower alkylene, which separates the group X from the nitrogen atom by at least two carbon atoms, R.sub.4 represents hydrogen, lower alkyl or optionally substituted phenyl-lower alkyl, Z represents the group --(C.dbd.O)-- or a single bond, Alk.sub.2 represents lower alkylene which separates the groups Z and Y preferably by from 2 to 4 carbon atoms, Y represents the group --(C.dbd.O)-- and Ar.sub.1 represents a monocyclic, carbocyclic or heterocyclic aryl radical, and salts of such compounds having salt-forming properties, have cardiovascular properties, especially coronary dilatory and anti-hypertensive properties.

Abstract: Novel 4-acylresorcinol ethers of the formula ##STR1## in which R.sub.1 is lower alkyl, alk is a hydroxyalkylene radical which can be interrupted by oxygen and R.sub.2 is 5-tetrazolyl, it being possible for the ring A to be additionally substituted by a lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy and/or halogen and for the ring B to be additionally substituted by lower alkyl, lower alkanoyl, lower alkoxy, lower alkoxycarbonyl, carboxyl, cyano, carbamyl, halogen and/or trifluoromethyl, and salts thereof have antiallergic properties and can be used as active compounds for medicaments. They are prepared by methods known as per se.

Abstract: Novel asymmetric thioethers of the formula ##STR1## in which the general symbols have the following meanings: a is an integer of from 1 to 7,R.sup.o represents hydrogen or C.sub.1-7 -alkanoyl,R.sup.1 represents C.sub.1-3 -alkyl which may be substituted at the terminal carbon atom by a free or acylated hydroxy group, by a halogen atom having an atomic number of at most 17, or by methoxy, or represents C.sub.1-3 -perfluoroalkyl,R.sup.2 represents an optionally unsaturated aliphatic radical having from 5 to 15 carbon atoms,A represents ethylene or alternatively, if R.sup.1 represents a halogenated radical and/or B represents phenylene or ethylene, a single bond or vinylene,B represents a single bond, ethynylene or phenylene,R.sup.3 represents hydroxy, C.sub.

Abstract: Piperazines of the formula ##STR1## and their salts, in which each of Ar.sub.1 and Ar.sub.2, independently of the other, represents phenyl that is unsubstituted or mono- or di-substituted by C.sub.1 -C.sub.7 -alkyl, C.sub.1 -C.sub.7 -alkoxy, cyano, halogen, trifluoromethyl, amino, C.sub.1 -C.sub.7 -alkylamino, di-C.sub.1 -C.sub.7 -alkylamino and/or by C.sub.1 -C.sub.7 -alkanoylamino, can be used as the active ingredients of medicaments and are manufactured in a manner known per se.

Abstract: The present invention relates to desulfatohirudins, to the preparation thereof, to pharmaceutical compositions containing these compounds, and to the use thereof. The desulfatohirudins of this invention correspond to hirudin in biological activity and are therefore particularly useful for inhibiting blood clotting.

Abstract: Solid, stable dosage forms consisting of a moisture- and temperature-sensitive core prepared from a medicament, or a mixture of medicaments, and excipients, and an elastic film coating which decomposes in aqueous solution, said elastic film coating substantially comprising(a) a water-soluble component consisting of20-60% of hydroxypropyl cellulose having an average molecular weight of 75,000, and(b) a water-insoluble component consisting of5-20% of an acrylic resin in the form of(b.sub.1) a 70:30 ethyl acrylate/methyl methacrylate copolymer having a molecular weight of 80,000, or(b.sub.2) a 30:70 to 70:30 methyl acrylate/methyl methacrylate copolymer having an average molecular weight of 500,000,20-60% of a lubricant,0.5-5% of a wetting agent,0-5% of a plasticizer,and optional additional excipients, and process for the preparation thereof.

Abstract: Pharmaceutical preparations containing compounds of formula I ##STR1## wherein ring A is unsubstituted or substituted, R.sub.1 and R.sub.2, independently of one another, each represents hydrogen, lower alkyl, aryl or heteroaryl, or R.sub.1 and R.sub.2 together represent lower alkylene optionally interrupted by oxygen, sulfur or optionally substituted nitrogen, Y is methylene, methylene mono- or disubstituted by lower alkyl, oxygen, sulfur, sulfinyl or sulfonyl, X represents a bivalent radical --S--C[--B--(Z).sub.n ].dbd.CH-- the sulfur group S of which is bonded directly to the .alpha.- or to the .beta.

Abstract: 2-Heterocyclyl-lower alkyl-6-hydroxy-lower alkyl-2-penem compounds of the formula ##STR1## in which R.sub.1 represents lower alkyl substituted by hydroxy or protected hydroxy, R.sub.2 represents carboxy or functionally modified carboxy, R.sub.3 represents an unsaturated monocyclic azaheterocyclyl radical bonded via a tertiary ring nitrogen atom to the radical -A- and A represents a lower alkylene radical, optical isomers of compounds of the formula (I), mixtures of these optical isomers and salts of such compounds of the formula (I) that contain a salt-forming group have antibiotic properties. The novel compounds can be used, for example, in the form of antibiotically active preparations for the treatment of infectious diseases. The novel compounds can be manufactured in a manner known per se.